Taru Hallinen

521 total citations
29 papers, 374 citations indexed

About

Taru Hallinen is a scholar working on Economics and Econometrics, Genetics and Surgery. According to data from OpenAlex, Taru Hallinen has authored 29 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 9 papers in Genetics and 6 papers in Surgery. Recurrent topics in Taru Hallinen's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Inflammatory Bowel Disease (8 papers) and Pharmaceutical Economics and Policy (5 papers). Taru Hallinen is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Inflammatory Bowel Disease (8 papers) and Pharmaceutical Economics and Policy (5 papers). Taru Hallinen collaborates with scholars based in Finland, United Kingdom and Switzerland. Taru Hallinen's co-authors include Erkki Soini, Kari Puolakka, Janne Martikainen, Kari K. Eklund, Markku Kauppi, Christian Asseburg, Pia Vihinen, K. Saarinen, Leo Niskanen and P Peura and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and BMJ Open.

In The Last Decade

Taru Hallinen

28 papers receiving 352 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Taru Hallinen Finland 12 102 87 83 81 70 29 374
Mirza I. Rahman United States 10 41 0.4× 92 1.1× 44 0.5× 69 0.9× 145 2.1× 18 379
Katherine Dea United States 12 32 0.3× 59 0.7× 78 0.9× 21 0.3× 58 0.8× 20 502
Ola Ghatnekar Sweden 13 141 1.4× 23 0.3× 34 0.4× 103 1.3× 23 0.3× 23 528
Su Been Lee United States 8 29 0.3× 143 1.6× 37 0.4× 65 0.8× 11 0.2× 24 379
Brian Bekker Hansen Denmark 13 32 0.3× 95 1.1× 53 0.6× 57 0.7× 60 0.9× 20 441
Antonio Aviña-Zubieta Canada 7 14 0.1× 163 1.9× 37 0.4× 53 0.7× 21 0.3× 16 377
Peter K. Schädlich Germany 12 85 0.8× 48 0.6× 16 0.2× 82 1.0× 14 0.2× 20 414
L. Pericleous Canada 10 68 0.7× 53 0.6× 23 0.3× 33 0.4× 8 0.1× 18 328
Cristina Lajas Spain 10 51 0.5× 278 3.2× 52 0.6× 32 0.4× 11 0.2× 26 478
Brittny Major United States 8 12 0.1× 134 1.5× 24 0.3× 49 0.6× 26 0.4× 14 335

Countries citing papers authored by Taru Hallinen

Since Specialization
Citations

This map shows the geographic impact of Taru Hallinen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taru Hallinen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taru Hallinen more than expected).

Fields of papers citing papers by Taru Hallinen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taru Hallinen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taru Hallinen. The network helps show where Taru Hallinen may publish in the future.

Co-authorship network of co-authors of Taru Hallinen

This figure shows the co-authorship network connecting the top 25 collaborators of Taru Hallinen. A scholar is included among the top collaborators of Taru Hallinen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taru Hallinen. Taru Hallinen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Björkesten, Clas-Göran af, Ritva Koskela, Aki Juhani Käräjämäki, et al.. (2025). Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study. European Journal of Gastroenterology & Hepatology. 37(4). 446–453. 1 indexed citations
2.
Hallinen, Taru, et al.. (2023). Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland. ClinicoEconomics and Outcomes Research. Volume 15. 1–13. 8 indexed citations
3.
4.
5.
Soini, Erkki, et al.. (2018). Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management. ClinicoEconomics and Outcomes Research. Volume 10. 279–292. 10 indexed citations
6.
7.
Soini, Erkki, Taru Hallinen, Mélanie Brignone, et al.. (2016). Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics & Outcomes Research. 17(3). 293–302. 18 indexed citations
8.
Hallinen, Taru, Erkki Soini, Miika Linna, & Samuli I. Saarni. (2016). Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. SpringerPlus. 5(1). 1354–1354. 8 indexed citations
9.
Soini, Erkki, et al.. (2015). Cost–Utility of First-Line Actinic Keratosis Treatments in Finland. Advances in Therapy. 32(5). 455–476. 25 indexed citations
10.
Hallinen, Taru, et al.. (2014). Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data. BMJ Open. 4(2). e004071–e004071. 21 indexed citations
11.
12.
Soini, Erkki, et al.. (2013). Administration costs of intravenous biologic drugs for rheumatoid arthritis. SpringerPlus. 2(1). 531–531. 18 indexed citations
13.
Soini, Erkki, et al.. (2011). Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. Journal of Medical Economics. 15(2). 340–351. 41 indexed citations
14.
15.
Hallinen, Taru, Erkki Soini, Kari K. Eklund, & Kari Puolakka. (2010). Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Lara D. Veeken. 49(4). 767–777. 49 indexed citations
16.
Hallinen, Taru, Erkki Soini, Janne Martikainen, Risto Ikäheimo, & Olli‐Pekka Ryynänen. (2009). Costs and quality of life effects of the first year of renal replacement therapy in one Finnish treatment centre. Journal of Medical Economics. 12(2). 136–140. 12 indexed citations
17.
Peura, P, Janne Martikainen, Erkki Soini, Taru Hallinen, & Leo Niskanen. (2008). Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Current Medical Research and Opinion. 24(6). 1823–1832. 23 indexed citations
18.
Hallinen, Taru, et al.. (2006). Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Current Medical Research and Opinion. 22(4). 683–692. 20 indexed citations
19.
Martikainen, Janne, et al.. (2005). Economic Evaluation of Temozolomide in the Treatment of Recurrent Glioblastoma Multiforme. PharmacoEconomics. 23(8). 803–815. 25 indexed citations
20.
Linnosmaa, Ismo, Raine Hermans, & Taru Hallinen. (2004). Price-cost margin in the pharmaceutical industry. The European Journal of Health Economics. 5(2). 122–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mirza I. Rahman Breakdown of academic impact, for papers by Katherine Dea Breakdown of academic impact, for papers by Ola Ghatnekar Breakdown of academic impact, for papers by Su Been Lee Breakdown of academic impact, for papers by Brian Bekker Hansen Breakdown of academic impact, for papers by Antonio Aviña-Zubieta Breakdown of academic impact, for papers by Peter K. Schädlich Breakdown of academic impact, for papers by L. Pericleous Breakdown of academic impact, for papers by Cristina Lajas Breakdown of academic impact, for papers by Brittny Major
Rankless by CCL
2026